The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

Abstract The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generation BTK inhibitors are being used and studied to imp...

Descripció completa

Dades bibliogràfiques

Autors principals:	Obada Ababneh, Hassan Abushukair, Aref Qarqash, Sebawe Syaj, Samer Al Hadidi
Format:	Artigo
Idioma:	Inglês
Publicat:	SAABRON PRESS 2022-05-01
Col·lecció:	Clinical Hematology International
Matèries:	Waldenstrom’s Macroglobulinemia Bruton tyrosine kinase inhibitors Ibrutinib Zanubrutinib
Accés en línia:	https://doi.org/10.1007/s44228-022-00007-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!